Healthcare News Roundup: Top Stories April 18–24, 2026

The week of April 18 to 24, 2026, delivered one of the most consequential stretches of healthcare news seen so far this year, anchored by a White House Executive Order signed on April 18 directing federal health agencies to accelerate regulatory access to psychedelic-based treatments for serious mental illness. That order, and the cascade of FDA actions it triggered within days, reshaped the mental health regulatory landscape in ways that will reverberate across clinical development pipelines, payer coverage frameworks, and provider training systems for years ahead.

Beyond the psychedelic policy pivot, the week produced two landmark FDA decisions, a record-breaking biotech IPO that signalled a reopening of public markets for life sciences, a major cross-border pharmaceutical deal between a US speciality company and Canada’s largest drug maker, sweeping new maternity safety standards from NHS England, and a pan-European digital health gathering in Berlin that drew more than 20,500 healthcare technology professionals. The breadth and speed of these developments underscore how rapidly clinical, policy, and market forces are converging in 2026.

Here are the top healthcare stories from April 18–24, 2026:

1. Trump Executive Order Fires Starting Gun on Psychedelic Therapy Regulation
2. FDA Grants Compass Pathways Rolling NDA Review for Psilocybin in Treatment-Resistant Depression
3. Merck’s Idvynso Gains FDA Approval as First Non-INSTI, Tenofovir-Free HIV Regimen
4. Regeneron’s Otarmeni Becomes First Gene Therapy for Genetic Hearing Loss
5. Kailera Therapeutics Raises $625M in Record-Breaking Biotech IPO
6. Cumberland Pharmaceuticals Sells Branded Portfolio to Canada’s Apotex for $100M
7. NHS England Mandates New Maternity Clinical Standards to Reduce Maternal Deaths
8. Digital Health Funding Hits $7.4B in Q1 2026 as AI Dominates Investment
9. DMEA 2026 in Berlin Draws 20,500 as Europe Advances Health Data Interoperability
10. Q1 2026 Biopharma M&A and IPO Markets Hit Multi-Year Highs
11. NHS HomeTest Programme Advances Plan for At-Home Diagnostics via NHS App
12. Rock Health: Q1 2026 Digital Health Average Deal Size Reaches Highest Level Since 2021

Trump Executive Order and FDA Regulatory Actions Accelerate Psychedelic Therapy Access

On April 18, 2026, President Trump signed an Executive Order directing the Department of Health and Human Services to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs for serious mental illness. The policy directive instructed the FDA Commissioner to provide Commissioner’s National Priority Vouchers to psychedelic drugs that have received Breakthrough Therapy designation, and directed the FDA and Drug Enforcement Administration to establish pathways for eligible patients to access these treatments under the Right to Try Act.

Building on the Executive Order, the FDA announced on April 24 a series of regulatory actions to support the development of serotonin-2A agonists and related products, a class of perception-altering psychedelic medications. The FDA also indicated it intends to release final guidance imminently to provide recommendations to sponsors developing these products, including foundational considerations for study design, data collection and generation, and patient monitoring in clinical investigations.

The Executive Order and the FDA’s follow-through actions represent a structural shift in how psychedelic compounds move through the regulatory apparatus, not simply a rhetorical endorsement. Practically, this means sponsors with Breakthrough Therapy designations may now access an accelerated review lane that compresses standard 6- to 10-month NDA review timelines to as little as one to two months. For patients with treatment-resistant depression, post-traumatic stress disorder, and other severe psychiatric conditions that have failed multiple prior therapies, this policy framework opens a meaningful near-term path to access. The implications for payers, prescribers, and healthcare systems managing serious mental illness caseloads are equally significant, as any approved psychedelic-assisted therapy will require dedicated infrastructure for supervised administration that existing clinic models are not yet built to absorb at scale.

Source: White House | https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/ and FDA | https://www.fda.gov/news-events/press-announcements/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order

Compass Pathways Secures FDA Rolling NDA Review and National Priority Voucher for COMP360 Psilocybin

On April 24, 2026, Compass Pathways announced that the FDA granted its NDA rolling review request and selected COMP360, its proprietary synthetic psilocybin formulation, for the Commissioner’s National Priority Voucher program for treatment-resistant depression. Companies selected for the voucher program are entitled to enhanced communications with the agency and a shortened review time of one to two months following NDA filing, while maintaining the FDA’s rigorous safety and efficacy standards.

COMP360 is designed to address treatment-resistant depression, a condition affecting approximately 4 million patients in the United States who have not responded adequately to two or more approved medications. Compass has generated positive results from two ongoing large, well-controlled Phase 3 clinical trials and is targeting completion of its rolling NDA submission in Q4 2026, with commercial launch readiness targeted for year-end. The company has also received FDA acceptance of an IND application for a late-stage PTSD trial, broadening its clinical footprint beyond TRD.

The significance of the voucher designation extends beyond the expedited timeline. It positions COMP360 as the most advanced psychedelic candidate in the US regulatory pipeline and dramatically shifts the competitive dynamics for other companies developing serotonin-2A agonists. Compass has kicked off a late-stage PTSD program and launched a US grant initiative to fund post-approval training for healthcare providers who will deliver COMP360 therapy, signalling that the company is already operationally preparing for real-world rollout rather than waiting for approval before addressing the substantial provider education and system-readiness gap that psychedelic-assisted therapy requires. Competing developers, including MAPS Public Benefit Corporation and others working on MDMA and ibogaine compounds, will now face a well-funded, clinically mature competitor with a regulatory acceleration advantage.

Source: Compass Pathways | https://ir.compasspathways.com/News–Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Granted-NDA-Rolling-Review-Request-and-Awarded-Commissioners-National-Priority-Voucher/default.aspx

Merck’s Idvynso Approved by FDA as First Non-INSTI, Tenofovir-Free HIV Regimen

On April 21, 2026, Merck announced that the FDA approved IDVYNSO (doravirine/islatravir), a new two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1 infection in adults. The approval covers virologically suppressed adults with HIV-1 RNA below 50 copies per mL on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.

Idvynso is the first and only complete two-drug therapy that is both non-integrase strand transfer inhibitor-based and tenofovir-free, offering a new alternative for patients who may benefit from avoiding certain drug classes or reducing treatment complexity. The FDA’s decision is supported by data from a pair of Phase 3 trials demonstrating noninferiority to standard three-drug regimens, including bictegravir/emtricitabine/tenofovir alafenamide. The drug will be available in pharmacies after May 11, 2026.

This approval carries meaningful clinical implications. Tenofovir-containing regimens, while effective, carry known risks of nephrotoxicity and bone mineral density loss with long-term use. For patients with renal vulnerability or those in later decades of treatment who have accumulated cumulative drug exposure, the ability to switch to a non-tenofovir, non-INSTI option expands the toolkit that infectious disease clinicians and HIV-specialist physicians can deploy. The approval also represents Merck’s attempt to carve a distinct position in a market where Gilead Sciences’ Biktarvy remains dominant. That the pivotal trial directly compared Idvynso to Biktarvy, demonstrating noninferiority, makes this a genuine competitor rather than a niche alternative, and payers and pharmacy benefit managers will be closely watching pricing and rebate negotiations as Merck prepares commercial launch.

Source: Merck | https://www.merck.com/news/fda-approves-mercks-once-daily-idvynso-doravirine-islatravir/

Regeneron’s Otarmeni Becomes FDA-Approved First Gene Therapy for Genetic Hearing Loss

On April 23, 2026, Regeneron Pharmaceuticals announced that the FDA granted accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy and second new molecular entity approved under the FDA Commissioner’s National Priority Voucher program. Otarmeni is indicated for pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss associated with molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear. In tandem with the approval, Regeneron announced Otarmeni will be made available at no cost to clinically eligible individuals in the United States.

The approval is based on pivotal results from the CHORD trial demonstrating that 80% of participants achieved or surpassed a hearing level meeting the primary endpoint, and with longer follow-up, 42% achieved normal hearing that included whispers. Otarmeni is the first FDA-approved example of a gene therapy to restore a neurosensory function to normal levels. The approval covers approximately 50 newborns per year in the United States who are affected by this ultra-rare condition.

Regeneron’s decision to offer Otarmeni at no cost in the US is a striking access strategy and a sharp departure from the pricing models that have defined other gene therapy approvals, where single-administration treatments often carry price tags exceeding $1 million. The OTOF-related hearing loss population is small, which shapes that calculus, but the precedent matters for how manufacturers position gene therapies for ultra-rare pediatric indications under growing scrutiny from payers, CMS, and international health technology assessment bodies. The European Medicines Agency has granted Orphan Drug Designation to Otarmeni, and regulatory submissions are planned in additional markets, meaning the pricing and access model will need to be adapted for NHS England’s value-based procurement framework and similar structures elsewhere.

Source: Regeneron Pharmaceuticals | https://investor.regeneron.com/news-releases/news-release-details/otarmenitm-lunsotogene-parvec-cwha-approved-fda-first-and-only

Key FDA Approvals and Regulatory Milestones: April 18–24, 2026

Kailera Therapeutics Raises $625M in Largest Biotech IPO in Nasdaq History

On April 17, 2026, Kailera Therapeutics, an obesity drug developer, raised $625 million in what is described as the largest biotech IPO in Nasdaq history. The IPO priced 39.1 million shares at $16, the top of its range, and the company was already up 63 per cent one day post-IPO. The Waltham, Massachusetts-based biotech is developing injectable and oral GLP-1 agonists, including ribupatide (KAI9531), a dual GIP and GLP-1 agonist licensed from China’s Hengrui Pharma, which is in Phase 3 testing as an injectable and had Phase 2 data disclosed for its oral form.

Kailera plans to pour $650 million into funding its three-trial, late-stage KaiNETIC programme for lead obesity injectable ribupatide into Q2 2028, and will dedicate $150 million to the development of its once-daily oral ribupatide pill. The IPO comes fairly soon after the company’s debut with a $400 million Series A and a $600 million Series B financing. Alamar Biosciences, a precision proteomics firm developing biomarker detection platforms, priced its own upsized IPO at $17 per share, raising $191.3 million in a round that was oversubscribed 11 times.

Kailera is staking its claim in the global obesity GLP-1 market, currently worth roughly $10 billion and projected to reach $66.57 billion by 2035, growing at a 23% compound annual growth rate. The back-to-back Kailera and Alamar listings signal a genuine, if selective, reopening of public biotech markets after years of constrained IPO activity. The divergence is notable: Kailera and Alamar traded above issue while several other 2026 IPO cohort members remain below their offering prices, confirming that investors are rewarding differentiated science and late-stage clinical data rather than early-stage promise alone. For hospital formulary managers and payers already navigating Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide, additional oral GLP-1 entrants moving through Phase 3 will complicate coverage and rebate strategy within two to three years.

Source: Fortune | https://fortune.com/2026/04/18/from-drought-to-demand-biotech-ipos-roar-back-with-kailera-and-alamar/

Cumberland Pharmaceuticals Sells Branded Portfolio to Canada’s Apotex for $100 Million

On April 23, 2026, Nashville-based Cumberland Pharmaceuticals announced it had entered into an agreement with an affiliate of Apotex, the largest Canadian-based pharmaceutical company, to acquire Cumberland’s full line of branded pharmaceuticals for cash consideration of $100 million, creating a platform to deliver speciality medicines across the United States. The portfolio being acquired includes established brands such as Kristalose, Caldolor, Sancuso, Vibativ, Acetadote, Vaprisol, and Talicia, prescribed across hospital, oncology, infectious disease, and gastroenterology settings. The transaction requires shareholder approval and customary regulatory clearances.

Cumberland will retain its development-stage pipeline, including ifetroban, a thromboxane antagonist being evaluated across multiple Phase 2 programs in cardiomyopathy associated with Duchenne muscular dystrophy, systemic sclerosis, and idiopathic pulmonary fibrosis. The company recently reported breakthrough results in its DMD cardiomyopathy Phase 2 study, with interactions currently underway with the FDA regarding the results and remaining requirements for approval. The program holds Orphan Drug, Rare Pediatric Disease, and Fast Track designations.

The strategic logic of this transaction runs in two directions simultaneously. For Cumberland, the $100 million cash consideration significantly exceeds the company’s recent market capitalisation of approximately $45 million, and the divestiture frees management bandwidth and capital to pursue ifetroban across rare disease indications where regulatory pathways are more defined and commercial competition less intense. For Toronto-headquartered Apotex, the acquisition significantly deepens its US hospital and speciality commercial infrastructure, shifting the company’s footprint beyond generics into a portfolio of differentiated branded hospital medicines. The cross-border nature of the deal also reflects a broader trend: Canadian pharmaceutical companies actively pursuing US commercial platform acquisitions as a faster route to speciality market presence than internal product development.

Source: Cumberland Pharmaceuticals | https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-strategic-transaction-to-integrate-commercial-business-with-apotex-302751769.html

NHS England Mandates New Maternity Clinical Standards to Tackle Maternal Deaths

NHS England announced on April 24, 2026, that every maternity service in England will be required to meet new clinical standards aimed at significantly reducing the number of women who die during or after pregnancy. All pregnant women will be offered an early risk assessment for venous thromboembolism, blood clots that are now the leading cause of maternal mortality, before their first antenatal appointment. Anyone identified as high risk will be offered thromboprophylaxis within 72 hours.

The new standards address conditions accounting for 52% of maternal deaths, including blood clots, strokes, cardiac disease, suicide, sepsis, obstetric haemorrhage, and preeclampsia. The latest figures show 252 maternal deaths from 2022 to 2024, compared with 257 between 2021 and 2023, figures that are 21% higher than in 2009 to 2011 and equate to 12.8 deaths for every 100,000 women giving birth. Between 2022 and 2024, maternal suicides remained the leading cause of maternal death occurring between 6 weeks and 1 year after the end of pregnancy. Research showed that improvements in care may have made a difference to the outcome for almost half of the women who died during or after pregnancy in 2021 to 2023. The NHS aims to have the measures fully rolled out across England by March 2027.

The decision to mandate pre-antenatal VTE risk assessment and require thromboprophylaxis within 72 hours for high-risk women represents one of the most clinically specific maternity safety interventions the NHS has introduced in recent years. The broader significance is institutional: NHS England is signalling that the era of guidance and recommendation in maternity care is giving way to enforceable standards with accountability routed through NHS trust boards and escalated to regional and national levels when local delivery falls short. For midwifery and obstetric teams already stretched by workforce pressures, the new requirements around structured mental health screening, epilepsy specialist access, and digital maternity record standards will require investment in both clinical capacity and IT infrastructure that NHS trusts at varying stages of financial stability may find difficult to absorb within the March 2027 timeframe.

Source: NHS England | https://www.england.nhs.uk/2026/04/nhs-overhauls-clinical-standards-to-reduce-maternal-deaths/

Q1 2026 Digital Health Funding Hits $7.4 Billion as AI Investment Dominates

Digital health funding reached $7.4 billion in Q1 2026, driven by AI drug discovery and M&A activity. The quarter saw AI-focused acquisitions and investments of notable scale, including Earendil Labs raising $787 million — the largest deal of the quarter — to support a deep learning platform that has already generated more than 40 therapeutic programs. The CMS-0057-F deadline mandating electronic prior authorization by January 2027 is driving significant investment into the revenue cycle and prior authorization technology space.

According to Rock Health, the average digital health deal size in Q1 2026 rose to $36.7 million, the highest amount tracked since 2021, compared with an average check size of $29.3 million in the prior year. Nearly 60% of the quarter’s digital health investment came from a dozen mega-deals, rounds worth $100 million or more. The concentration of capital in fewer, larger deals reflects a market that is active but deeply selective, rewarding companies with proven commercial traction and established hospital or payer contracts over earlier-stage platform plays.

The strategic implication for health system CIOs and digital health founders alike is that the funding environment rewards demonstrated deployment at scale over technological novelty. The Adoption Premium is visible in acquisition pricing: DeepHealth’s $269 million acquisition of Gleamer was driven by a footprint of more than 700 hospital contracts. For MedTech founders seeking Series A or B capital, the practical message is that payer alignment, CMS billing pathway clarity, and a quantifiable reduction in administrative burden are increasingly more important to institutional investors than algorithmic novelty or platform architecture claims.

Source: HIT Consultant / CB Insights | https://hitconsultant.net/2026/04/20/digital-health-funding-q1-2026-ai-ma-rebound/

DMEA 2026 in Berlin Advances European Digital Health Interoperability Agenda

DMEA 2026, Europe’s largest digital health conference and trade fair, was held April 21 to 23 at Messe Berlin in Germany. The event drew approximately 900 exhibitors and more than 20,500 visitors, covering HIS systems, AI applications in clinical workflows, smart hospital solutions, and digital transformation initiatives for medicine and hospitals. The conference served as the primary European platform for conversations around the EU’s European Health Data Space regulation, EUDAMED implementation, AI Act compliance in healthcare settings, and the advancement of sovereign cloud infrastructure for clinical data.

Key themes at DMEA this year included the European Commission’s targeted MDR/IVDR simplification efforts, including the removal of the rigid five-year certificate validity cap in favour of continuous, risk-based surveillance to ease notified-body bottlenecks. The EIC awarded 118 million euros in Pathfinder funding to 30 breakthrough projects, with a notable share going to biotechnology for healthy ageing and modular multi-robot surgical assistance platforms. BD launched Pyxis Pro medication dispensing and Incada Connected Care across Europe, built on cloud infrastructure, reflecting hospital buyers’ focus on integrated medication management and connected-care platforms.

DMEA’s significance in 2026 extends beyond exhibition. The conference has become the de facto policy forum where European health IT executives, hospital CIOs, and regulators negotiate the practical implementation of the European Health Data Space, a regulation that will have far-reaching consequences for how patient data is shared across member states for research, clinical decision support, and regulatory purposes. For US-based health technology companies seeking European market entry, the EUDAMED go-live countdown and AI Act compliance requirements for high-risk clinical AI systems represent a regulatory complexity that is now inseparable from commercial strategy. Non-European companies that fail to build EHDS-compatible data governance architectures into product design now risk costly retrofitting later.

Source: DMEA Official | https://www.dmea.de/en and Nelson Advisors European MedTech HealthTech | https://www.healthcare.digital/single-post/this-week-in-european-medtech-and-healthtech-10th-april-2026

Biopharma M&A Momentum Builds as Q1 2026 Reaches Multi-Year Highs

Biopharma venture funding totaled $5.2 billion in Q1 2026, while biopharma licensing reached $77.3 billion in announced value, with upfront cash representing 6% of total deal value. Biopharma M&A totaled $15.6 billion across 19 deals, and six biopharma IPOs raised $1.8 billion, already surpassing full-year 2025 proceeds. In medtech, venture funding totaled $2.2 billion across 66 rounds in Q1 2026, while MedTech M&A totaled $26.6 billion across 37 deals.

Seven transactions worth a combined $29 billion occurred in a compressed two-week period in late March, a burst that analysts at Jefferies described as confirmation that 2026 is a prime year for M&A. Among the largest deals: Merck paid $6.7 billion to acquire Terns Pharmaceuticals and its oral leukemia candidate TERN-701, while Eli Lilly offered $6.3 billion upfront, plus $1.5 billion in potential contingent value right payments, for Centessa Pharmaceuticals and its portfolio of sleep disorder treatments.

The underlying driver in deal activity is well-established: major pharmaceutical companies facing patent cliffs on blockbuster products are in competitive pursuit of late-stage assets to replenish revenue. Merck’s Keytruda faces loss of exclusivity by the end of this decade, making its acquisition pace across the past ten months — three transactions, each exceeding $6 billion — a structured response to a known commercial threat rather than opportunistic deal-making. For biotech founders and investors, the resulting competition among well-capitalised acquirers for a finite pool of credible late-stage programs is a structural tailwind that supports both private financing valuations and IPO pricing, as the Kailera Therapeutics debut demonstrated.

Source: J.P. Morgan Biopharma and Medtech Licensing and Venture Report | https://www.jpmorgan.com/insights/markets-and-economy/outlook/biopharma-medtech-deal-reports and Fierce Pharma | https://www.fiercepharma.com/pharma/march-ma-surge-triggers-high-expectations-2026

NHS HomeTest Programme Moves Toward At-Home Diagnostics via NHS App

The NHS is advancing plans for a HomeTest service that would allow patients to order tests across seven medical specialities, complete them at home, and receive results directly via the NHS app. Initial tests under exploration may include liver function, cholesterol levels, sexually transmitted diseases, prostate-specific antigen blood checks for prostate cancer monitoring, and tests related to rheumatology, fertility and menstrual issues for women, and blood tests for antibiotic-resistant superbugs such as MRSA. The government projects that once fully implemented, related digital access measures could free up 500,000 hospital appointments annually.

From April 2026, NHS England requires providers to fully adopt all existing NHS App capabilities as a priority, including making at least 95% of appointments available after appropriate triage via the NHS app across all care settings. Providers should also ensure full coverage of patients’ abilities to manage their medicines, view waiting times and contact information, receive and complete pre- and post-appointment questionnaires, and implement digital patient-initiated follow-up in line with guidance. This should be in place no later than the end of 2028 to 2029.

The HomeTest programme, if implemented at scale, could substantively alter the pathway between a patient’s first symptom awareness and clinical diagnosis. The NHS’s focus on liver function, cholesterol, PSA, and antibiotic resistance testing in particular reflects an attempt to shift detection of chronic disease risk factors and infectious disease threats further upstream in the care pathway, before patients present to GPs or emergency departments with advanced conditions. The practical challenge lies in ensuring equitable access: digital health tools deployed through smartphone apps systematically disadvantage older, less digitally literate populations who already bear disproportionate chronic disease burden. NHS England will need robust non-digital parallel pathways if HomeTest is not to deepen health inequalities even as it eases hospital appointment load.

Source: NHS England Medium Term Planning Framework | https://www.england.nhs.uk/long-read/medium-term-planning-framework-delivering-change-together-2026-27-to-2028-29/ and BritBrief | https://britbrief.co.uk/health/nhs/nhs-to-launch-at-home-health-tests-via-app-from-april.html

Closing Thought

The week of April 18 to 24, 2026, confirmed that the structural forces shaping global healthcare — psychedelic therapy regulation, gene therapy access economics, GLP-1 obesity market competition, NHS digital transformation, and European health data governance are accelerating simultaneously. Clinicians, investors, health system executives, and policy researchers should watch the Compass Pathways rolling NDA filing timeline, NHS maternity standard enforcement mechanisms, EHDS implementation milestones, and the first commercial patients receiving Otarmeni gene therapy in the weeks immediately ahead. Stay tuned for next week’s healthcare news roundup.